Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(11):1398–1400. doi: 10.1038/bjc.1996.265

WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer.

M Wan 1, K F Cofer 1, L Dubeau 1
PMCID: PMC2074480  PMID: 8645586

Abstract

Mutations in the WAF1/CIP1 gene were not found in 36 ovarian carcinomas, including tumours with loss of heterozygosity at the WAF1/CIP1 locus and/or lacking p53 mutations. In addition, no association was demonstrable between a polymorphism in a conserved region of the WAF1/CIP1 gene and ovarian carcinoma.

Full text

PDF
1398

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chedid M., Michieli P., Lengel C., Huppi K., Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 1994 Oct;9(10):3021–3024. [PubMed] [Google Scholar]
  2. Cliby W., Ritland S., Hartmann L., Dodson M., Halling K. C., Keeney G., Podratz K. C., Jenkins R. B. Human epithelial ovarian cancer allelotype. Cancer Res. 1993 May 15;53(10 Suppl):2393–2398. [PubMed] [Google Scholar]
  3. Dodson M. K., Cliby W. A., Xu H. J., DeLacey K. A., Hu S. X., Keeney G. L., Li J., Podratz K. C., Jenkins R. B., Benedict W. F. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res. 1994 Feb 1;54(3):610–613. [PubMed] [Google Scholar]
  4. Foulkes W. D., Ragoussis J., Stamp G. W., Allan G. J., Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer. 1993 Mar;67(3):551–559. doi: 10.1038/bjc.1993.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805–816. doi: 10.1016/0092-8674(93)90499-g. [DOI] [PubMed] [Google Scholar]
  6. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 1994 Dec 16;266(5192):1821–1828. doi: 10.1126/science.7997877. [DOI] [PubMed] [Google Scholar]
  7. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  8. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  9. Kim T. M., Benedict W. F., Xu H. J., Hu S. X., Gosewehr J., Velicescu M., Yin E., Zheng J., D'Ablaing G., Dubeau L. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res. 1994 Feb 1;54(3):605–609. [PubMed] [Google Scholar]
  10. Li R., Waga S., Hannon G. J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature. 1994 Oct 6;371(6497):534–537. doi: 10.1038/371534a0. [DOI] [PubMed] [Google Scholar]
  11. Li Y. J., Laurent-Puig P., Salmon R. J., Thomas G., Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene. 1995 Feb 2;10(3):599–601. [PubMed] [Google Scholar]
  12. Michieli P., Chedid M., Lin D., Pierce J. H., Mercer W. E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994 Jul 1;54(13):3391–3395. [PubMed] [Google Scholar]
  13. Mousses S., Ozçelik H., Lee P. D., Malkin D., Bull S. B., Andrulis I. L. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 1995 Jun;4(6):1089–1092. doi: 10.1093/hmg/4.6.1089. [DOI] [PubMed] [Google Scholar]
  14. Shiohara M., el-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994 Dec 1;84(11):3781–3784. [PubMed] [Google Scholar]
  15. Waga S., Hannon G. J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994 Jun 16;369(6481):574–578. doi: 10.1038/369574a0. [DOI] [PubMed] [Google Scholar]
  16. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993 Dec 16;366(6456):701–704. doi: 10.1038/366701a0. [DOI] [PubMed] [Google Scholar]
  17. Zheng J., Benedict W. F., Xu H. J., Hu S. X., Kim T. M., Velicescu M., Wan M., Cofer K. F., Dubeau L. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst. 1995 Aug 2;87(15):1146–1153. doi: 10.1093/jnci/87.15.1146. [DOI] [PubMed] [Google Scholar]
  18. el-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994 Mar 1;54(5):1169–1174. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES